Literature DB >> 16730330

Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo.

Akihide Atsumi1, Akihiro Tomita, Hitoshi Kiyoi, Tomoki Naoe.   

Abstract

PML-RARalpha is a chimeric transcription factor tightly associated with acute promyelocytic leukemia. PML-RARalpha plays an important role in the aberrant transcription repression on the target genes of wild-type retinoic acid receptors. Here, we demonstrated that HDAC3, one component of the N-CoR transcription repressor complex, is a key regulator of the transcription repression by PML-RARalphain vivo. Using immunoprecipitation, we demonstrated that PML-RARalpha interacts with N-CoR/HDAC3 in vivo without ligand. Next, using chromatin immunoprecipitation (ChIP) assay, this N-CoR/HDAC3 co-repressor complex was recruited to the endogenous target promoters (RARbeta and CYP26) through PML-RARalpha. The neighboring histones were de-acetylated and gene expression was repressed. When HDAC3 protein was knocked down by RNA interference in PML-RARalpha-expressing cells, the endogenous target genes were significantly activated, which was also confirmed by promoter-luciferase reporter assay. These results provide evidence to show that the N-CoR/HDAC3 co-repressor complex is involved in the aberrant transcription regulation in PML-RARalpha-expressing cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16730330     DOI: 10.1016/j.bbrc.2006.05.047

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

1.  Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy.

Authors:  Akihiro Tomita; Junji Hiraga; Hitoshi Kiyoi; Manabu Ninomiya; Takumi Sugimoto; Masafumi Ito; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 2.  Dietary manipulation of histone structure and function.

Authors:  Barbara Delage; Roderick H Dashwood
Journal:  Annu Rev Nutr       Date:  2008       Impact factor: 11.848

Review 3.  Histone deacetylases and cancer.

Authors:  Bruna Barneda-Zahonero; Maribel Parra
Journal:  Mol Oncol       Date:  2012-08-27       Impact factor: 6.603

4.  Aldose Reductase Acts as a Selective Derepressor of PPARγ and the Retinoic Acid Receptor.

Authors:  Devi Thiagarajan; Radha Ananthakrishnan; Jinghua Zhang; Karen M O'Shea; Nosirudeen Quadri; Qing Li; Kelli Sas; Xiao Jing; Rosa Rosario; Subramaniam Pennathur; Ann Marie Schmidt; Ravichandran Ramasamy
Journal:  Cell Rep       Date:  2016-03-24       Impact factor: 9.423

Review 5.  Metal-dependent Deacetylases: Cancer and Epigenetic Regulators.

Authors:  Jeffrey E López; Eric D Sullivan; Carol A Fierke
Journal:  ACS Chem Biol       Date:  2016-03-18       Impact factor: 5.100

Review 6.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 7.  Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.

Authors:  Madeline M Wong; Chun Guo; Jinsong Zhang
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

Review 8.  Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.

Authors:  Akihiro Tomita; Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2013-05-14       Impact factor: 2.490

9.  HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.

Authors:  Cassandra A Godman; Rashmi Joshi; Brendan R Tierney; Emily Greenspan; Theodore P Rasmussen; Hsin-Wei Wang; Dong-Guk Shin; Daniel W Rosenberg; Charles Giardina
Journal:  Cancer Biol Ther       Date:  2008-10-07       Impact factor: 4.742

Review 10.  Targeting of histone deacetylases in brain tumors.

Authors:  Jonas Ecker; Olaf Witt; Till Milde
Journal:  CNS Oncol       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.